Journal
NUTRIENTS
Volume 12, Issue 6, Pages -Publisher
MDPI
DOI: 10.3390/nu12061747
Keywords
allergen sensitization; allergic disease; eczema; hereditary risk; infant; prevention; randomized controlled trial; vitamin D; wheeze
Categories
Funding
- Medical Research Future Fund Next Generation Clinical Researchers Program [APP1144544]
- Telethon-New Children's Hospital Research Fund
- Asthma Foundation of Western Australia
- Princess Margaret Hospital Foundation
Ask authors/readers for more resources
Lower vitamin D status at birth and during infancy has been associated with increased incidence of eczema and food allergies. The aim of this study was to investigate the effect of early infancy vitamin D supplementation on allergic disease outcomes in infants at hereditary risk of allergic disease, but who had sufficient vitamin D levels at birth. Here, we report the early childhood follow-up to 2.5 years of age of high-risk infants who participated in a double-blinded, randomized controlled trial. For inclusion in this trial, late gestation (36-40 weeks) maternal 25-hydroxyvitamin D levels needed to be >= 50 nmol/L. Infants were randomized to either oral vitamin D supplementation of 400 IU/day (n= 97) or a placebo (n= 98) for the first six months of life. Vitamin D levels and allergic disease outcomes were followed up. There were no statistically significant differences in incidence of any medically diagnosed allergic disease outcomes or allergen sensitization rates between the vitamin D-supplemented and placebo groups at either 1 year or at 2.5 years of age. In conclusion, for allergy high-risk infants who had sufficient vitamin D status at birth, early infancy oral vitamin D supplementation does not appear to reduce the development of early childhood allergic disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available